Compugen Ltd (CGEN) stock
Close on Nov 11, 2026Market cap $197.62MP/E 5.5Yield –
Compugen Ltd grew revenue 161.1% to $72.76M over fiscal 2025. Free cash flow was $31.33M, down 36.7% from a year earlier. At the latest close the market valued the company at $197.62M, 5.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $197.62M
- P/E ratio
- 5.5
- Price to sales
- 2.72
- Price to book
- 2.23
- Dividend yield
- –
- Free cash flow yield
- 15.85%
Fundamentals
- Revenue
- $72.76M
- Net income
- $35.34M
- EPS, diluted
- $0.38
- Free cash flow
- $31.33M
Trading
- Previous close
- $2.09
- Open
- $2.09
- Day's range
- $2.07 – $2.12
- Volume
- 211,131
- Average volume (20 days)
- 242,885
- Beta (5 years)
- 1.61
- 52-week range
- $1.43 – $3.23
- RSI (14 days)
- 50.7
- Volatility (1 year)
- 64.5%
- Relative volume
- 0.86×
- WACC
- 12.9%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CGEN | S&P 500 | Difference | CGEN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.9% | -2.4% | +0.5 pts | ||
| 3 months | -12.9% | -1.2% | −11.8 pts | ||
| Year to date | +36.6% | +12.3% | +24.3 pts | ||
| 1 year | +21.5% | +12.4% | +9.1 pts | ||
| 3 years | +262.2% | +78.8% | +183.4 pts | +53.6% | +21.4% |
| 5 years | -70.8% | +75.2% | −146.0 pts | -21.8% | +11.9% |
| 10 years | -68.6% | +311.1% | −379.7 pts | -10.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Compugen filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Compugen
Biological Products, (No Diagnostic Substances)
Compugen Ltd. is a clinical-stage biotechnology company that discovers and develops therapeutic candidates for cancer immunotherapy and immuno-oncology. The company operates in a single operating segment and utilizes an artificial intelligence and machine learning discovery platform called Unigen to identify novel drug targets. Its primary therapeutic pipeline programs include COM701, COM902, GS-0321, and rilvegostomig, a bispecific antibody developed with a partner. Compugen collaborates with and licenses its therapeutic assets to major pharmaceutical and biotechnology companies, including AstraZeneca and Gilead Sciences.
Company profile, executives and historyCompugen stock: common questions
What is Compugen's stock price?
CGEN closed at $2.09 on Nov 11, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $1.43 and $3.23.
What is Compugen's market cap?
Compugen was worth $197.62M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CGEN's P/E ratio?
CGEN trades at 5.5 times earnings, based on diluted earnings per share of $0.38 over fiscal 2025.
How much revenue does Compugen make?
Compugen reported revenue of $72.76M for fiscal 2025, up 161.1% from a year earlier.
Does Compugen pay a dividend?
No. Compugen has not paid a cash dividend over the last twelve months.
How has CGEN stock performed over the past year?
Including dividends, CGEN returned +21.5% over the past year, against +12.4% for the S&P 500.
How many CGEN shares are sold short?
3M shares were sold short at the latest FINRA report, 2.69% of the float, or 9.7 days of average trading volume.
Who are Compugen's competitors?
Companies most similar to Compugen by business, industry and size include RXRX, CSBR, STRO, GLUE, ADAPY.
See a number that looks wrong?